__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________</
LEQVIO® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1
This page is intended only for UK healthcare professionals contracted by Novartis to participate in a Novartis promotional activity.
Welcome to the speaker resource centre for LEQVIO. On this page you will find downloadable assets for your Novartis-organised meetings. Please do not distribute these assets.
‘Meeting in a box’ presentations
How can LEQVIO® ▼ (inclisiran) help when statins alone are not enough?
Lowering LDL-C in Primary Care
Download this meeting-in-a-box which contains a set of slides to enable you to run a meeting on How can LEQVIO® help when statins alone are not enough? Lowering LDL-C in Primary Care. The slide deck offers information about the LDL-C management, information regarding the efficacy and safety profile, dosing and administration of LEQVIO® and specific guidance on the management of patients with dyslipidaemia.
Click here to download the presentation.
How can LEQVIO® ▼ (inclisiran) help when statins alone are not enough?
Lowering LDL-C in Secondary Care
Download this meeting-in-a-box which contains a set of slides to enable you to run a meeting on How can LEQVIO® help when statins alone are not enough? Lowering LDL-C in Secondary Care. The slide deck offers information about the LDL-C management, information regarding the efficacy and safety profile, dosing and administration of LEQVIO® and specific guidance on the management of patients with dyslipidaemia.
Click here to download the presentation.
LEQVIO® ▼(inclisiran) master slide library
LEQVIO® ▼ (inclisiran) master slide library
Take a deep dive into all aspects of ASCVD and LEQVIO®. This Master Slide library can be used to build your own presentation, following discussion with your Novartis contact and using the guidance provided within. This presentation provides in-depth background information covering everything from the pathophysiology of ASCVD, the importance of LDL-C as a modifiable risk factor as well as the role of LEQVIO in helping patients reach their target LDL-C goals..
Click here to download the presentation.
ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; NHS, National Health Service; NICE, National Institute for Health and Care Excellence.
Reference
- Leqvio® Summary of Product Characteristics.